phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-162Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWФармакогенетика артериальной гипертонии: особенности фармакогенетики торасемидаPharmacogenetics of arterial hypertension: pharmacogenetic of torasemideЛеоноваМ. В.LeonovaM. V.

Леонова Марина Васильевна — д.м.н., профессор, член-корреспондент РАЕН, профессор кафедры клинической фармакологии.

г. Москвател. +7(915)320-43-79 

Department of Clinical Pharmacology

 

anti23@mail.ruРНИМУ им. Н.И. ПироговаРоссияRussian stste medical universityRussian Federation2016250320200148Copyright © Леонова М.В., 20202020Леонова М.В.Leonova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/162

В статье обсуждаются вопросы фармакогенетики артериальной гипертонии (АГ) и фармакологического ответа на антигипертензивные препараты, в частности влияния фармакогенетического полиморфизма различных генов в эффективности и безопасности петлевого диуретика торасемида. Представлен обзор научных данных по влиянию генетического полиморфизма генов метаболизирующего фермента CYP2C9 и анионного транспортера OAT на фармакокинетику препарата (печёночный и почечный клиренс), а также на фармакодинамику (выраженность диуретического и салуретического эффектов).

The article discusses the pharmacogenetics of arterial hypertension and pharmacological response to antihypertensive drugs, in particular the influence of pharmacogenetic polymorphism of different genes in the efficacy and safety of new loop diuretic torasemide. A review of the scientific evidence on the influence of genetic polymorphisms of genes metabolizsing enzyme CYP2C9 and anion transporter OAT on the pharmacokinetics of the drug (hepatic and renal clearance) and the pharmacodynamics (pronounced of diuretic and saluretic effects).

фармакогенетикаартериальная гипертонияторасемидфармакогенетический полиморфизмметаболизмтранспортерpharmacogeneticshypertensiontorasemidepharmacogenetic polymorphismmetabolismanion transporterReferencesArnett D.K., Claas S.A., Glasser S.P. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol. 2006;44(2):107-18.Arnett D.K., Claas S.A., Glasser S.P. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol. 2006;44(2):107-18.Kamide K., Yang J., Matayoshi T. et al. Genetic polymorphisms of L-type calcium channel a1C and a1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers. Circ J 2009; 76: 732—740Kamide K., Yang J., Matayoshi T. et al. Genetic polymorphisms of L-type calcium channel a1C and a1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers. Circ J 2009; 76: 732—740Riddle E.L., Rana B.K., Murthy K.K. et al. Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives. Hypertension. 2006;47:415-420.Riddle E.L., Rana B.K., Murthy K.K. et al. Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives. Hypertension. 2006;47:415-420.Sugimoto K., Katsuya T., Kamide K. et al. Promoter polymorphism of RGS2 gene is associated with change of blood pressure in subjects with antihypertensive treatment: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes study. Int J Hypertens 2010:196307.Sugimoto K., Katsuya T., Kamide K. et al. Promoter polymorphism of RGS2 gene is associated with change of blood pressure in subjects with antihypertensive treatment: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes study. Int J Hypertens 2010:196307.Turner S.T., Schwartz G.L., Chapman A.B. et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertension 2001;19: 1—11.Turner S.T., Schwartz G.L., Chapman A.B. et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertension 2001;19: 1—11.Johnson J.A. Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics 2010; 11: 487—491.Johnson J.A. Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics 2010; 11: 487—491.Kamide K., Kawano Y., Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertension Research.2012;35:796—799.Kamide K., Kawano Y., Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertension Research.2012;35:796—799.Torrellas C., Carril J.C., Cacabelos R. Benefits of Pharmacogenetics in the Management of Hypertension. J Pharmacogenomics Pharmacoproteomics 2014, 5:1-7.Torrellas C., Carril J.C., Cacabelos R. Benefits of Pharmacogenetics in the Management of Hypertension. J Pharmacogenomics Pharmacoproteomics 2014, 5:1-7.Polimanti R, Iorio A., Piacentini S. et al. Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014;15(2):157-67.Polimanti R, Iorio A., Piacentini S. et al. Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014;15(2):157-67.Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 335: 827—838, 1990Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 335: 827—838, 1990Mancia G., Fagard R. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31: 1281—1357.Mancia G., Fagard R. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31: 1281—1357.Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010.Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010.Kent S.T., Shimbo D., Huang L. et al. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007—2010. PLoS ONE 9(8): e105888.Kent S.T., Shimbo D., Huang L. et al. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007—2010. PLoS ONE 9(8): e105888.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc.Drugs Ther.1993;7 (Suppl 1): 63-8.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc.Drugs Ther.1993;7 (Suppl 1): 63-8.Friedel H.A., Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991;41(1):81-103.Friedel H.A., Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991;41(1):81-103.Dunn C.J., Fitton A., Brogden R.N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995;49:121-42.Dunn C.J., Fitton A., Brogden R.N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995;49:121-42.Uchida T., Yamanaga K., Nishikawa M. et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991;205:145-50.Uchida T., Yamanaga K., Nishikawa M. et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991;205:145-50.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc.Drugs Ther. 1993;7(Suppl 1):63-8.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc.Drugs Ther. 1993;7(Suppl 1):63-8.Luft F.C. Torasemide in the treatment of arterial hypertension. J.Cardiovasc.Pharmacol. 1993; 22(Suppl 3):S32-S39.Luft F.C. Torasemide in the treatment of arterial hypertension. J.Cardiovasc.Pharmacol. 1993; 22(Suppl 3):S32-S39.Castañeda-Hernández G., Caillé G., du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin. Pharmacokinet. 1994;26(2):135-43.Castañeda-Hernández G., Caillé G., du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin. Pharmacokinet. 1994;26(2):135-43.Schwartz S., Brater D.C., Pound D. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin. Pharmacol. Ther. 1993;54:90-7.Schwartz S., Brater D.C., Pound D. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin. Pharmacol. Ther. 1993;54:90-7.Miners J.O., Rees D.L., Valente L. et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol. Exp. Ther. 1995;272:1076-81.Miners J.O., Rees D.L., Valente L. et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol. Exp. Ther. 1995;272:1076-81.Miners J.O., Coulter S., Birkett D.J. et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000;10:267-70.Miners J.O., Coulter S., Birkett D.J. et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000;10:267-70.Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.Werner D., Werner U., Meybaum A et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet. 2008;47(5):323-32.Werner D., Werner U., Meybaum A et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet. 2008;47(5):323-32.Vormfelde S.V., Schirmer M., Hagos Y. et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin. Pharmacol. 2006;62(3): 323-35Vormfelde S.V., Schirmer M., Hagos Y. et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin. Pharmacol. 2006;62(3): 323-35Burckhardt G. Drug transport by Organic Anion Transporters (OATs). Pharmacol. Ther. 2012;136(1):106-30.Burckhardt G. Drug transport by Organic Anion Transporters (OATs). Pharmacol. Ther. 2012;136(1):106-30.Hasannejad H., Takeda M., Taki K. et al. Interactions of human organic anion transporters with diuretics. J Pharmacol. Exp. Ther. 2004;308:1021—9.Hasannejad H., Takeda M., Taki K. et al. Interactions of human organic anion transporters with diuretics. J Pharmacol. Exp. Ther. 2004;308:1021—9.Vormfelde S.V., Schirmer M., Hagos Y. et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006;62(3): 323—335.Vormfelde S.V., Schirmer M., Hagos Y. et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006;62(3): 323—335.Vormfelde S.V., Toliat M.R., Schirmer M. et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharm & Ther 2008;83(6):815-817.Vormfelde S.V., Toliat M.R., Schirmer M. et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharm & Ther 2008;83(6):815-817.Vormfelde S.V., Engelhardt S., Zirk A. et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 2004;76:557-66.Vormfelde S.V., Engelhardt S., Zirk A. et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 2004;76:557-66.

The authors declare that there are no conflicts of interest present.